الفهرس 
Aim of The WorkOnly 14 pages are availabe for public view
 |  | from | 178 |  |  |
| | | from | 178 | | |
Abstract
Psoriasis is a chronic, immune-mediated, inflammatory skin
condition, that causes the rapid proliferation of skin cells and forming
plaques of thickened skin covered in scales. It affects 2.7% of the
world’s population.
OVOL1, one of family genes that encoding C2H2 zinc finger
transcription factors in animals, it is expressed in multiple epithelial
tissues, including epidermis, hair follicles, renal epithelium and testes,
and its mouse homolog Ovol1 is functionally required for proper
embryonic epidermal development.
Specifically, Ovol1 is expressed in the transiently proliferative
epidermal intermediate and spinous cells, and its germline ablation
results in a thickened epidermis with expanded early differentiating
cells (spinous layers) and a transient delay in barrier acquisition that is
resolved by birth.
Skin epithelia-specific deletion of Ovol1 impairs the epidermal
barrier and aggravates psoriasis-like skin inflammation in mice in part
by enhancing neutrophil accumulation and abscess formation.
Filaggrin (FLG), encoding a keratin filament associated protein
(Filaggrin), In addition to terminal differentiation and barrier function
of the epidermis, Filaggrin has several other beneficial roles to play.
several amino acids are produced by degradation of Filaggrin that act
as natural moisturizing factors in the stratum corneum and also reduce
the skin surface pH also acts as putative ultraviolet photoprotector.
OVOL1 and Filaggrin have been associated with many inflammatory skin lesions. Little is known about their interaction in psoriasis pathogenesis. So this work aimed to study the immunohistochemical expression of OVOL1 and Filaggrin in
psoriasis, find out the possible relation between them, and to correlate
their expressions with the available clinicopathological data.
The present study included 60subjects; 30 patients with psoriasis vulgaris and 30 age and gender matched healthy subjects as a control group.
Inclusion criteria included cases diagnosed with psoriasis
vulgaris irrespective for age and gender. The selected cases were
either newly diagnosed with psoriasis vulgaris or previously
diagnosed and stopped any topical (2 weeks) or systemic (6 weeks)
treatment for psoriasis before joining the study.